GSWM
NBIX icon

Golden State Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Golden State Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8K Hold
183
– – ﹤0.01% 852
2026
Q1 		$24.1K Hold
183
– – ﹤0.01% 872
2025
Q4 		$26K Hold
183
– – ﹤0.01% 867
2025
Q3 		$25.7K Buy
183
+100
+120% +$13.6K ﹤0.01% 854
2025
Q2 		$10.4K Sell
83
-100
-55% -$11.5K ﹤0.01% 1068
2025
Q1 		$20.2K Hold
183
– – ﹤0.01% 795
2024
Q4 		$25K Buy
+183
New +$22.6K ﹤0.01% 714
2020
Q2 		– Sell
-54
Closed -$5K – 683
2020
Q1 		$5K Buy
+54
New +$5.29K ﹤0.01% 746
2019
Q4 		– Sell
-54
Closed -$5K – 618
2019
Q3 		$5K Sell
54
-946
-95% -$88.4K ﹤0.01% 863
2019
Q2 		$84K Buy
1,000
+500
+100% +$41.1K 0.03% 355
2019
Q1 		$44K Buy
+500
New +$41.8K 0.01% 476

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Golden State Wealth Management's NBIX Position: Q2 2026 in Review

Golden State Wealth Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 183 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Golden State Wealth Management first reported a position in NBIX in Q1 2019 and has held it in 11 quarters since. The position peaked at $84K in Q2 2019. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Golden State Wealth Management held 183 shares of Neurocrine Biosciences worth $30.8K as of Q2 2026.
  • Golden State Wealth Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #852 holding.
  • Golden State Wealth Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 11 quarters since.
  • Golden State Wealth Management's Neurocrine Biosciences position peaked at $84K in Q2 2019.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.